Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
Dr. Gadam was most recently chief technical officer at Cargo Therapeutics and responsible for technical operations for the cell therapy portfolio. Prior to Cargo, he held the position of vice president and head of cell therapy global manufacturing sciences & technology at Juno therapeutics, a Celgene company and Bristol Myers Squibb where he was instrumental in launch of two cell therapy commercial CAR-T products. During his tenure at Genetech/Roche from 2006-2018, he held positions of increasing responsibility across technical development and manufacturing advancing multiple biologics programs. Dr. Gadam started his career at Merck & Company in developing bioprocesses for vaccines. He holds a Ph.D. in Biochemical Engineering from Rensselaer Polytechnic Institute, a M.S. in Chemical Engineering from West Virginia University and a B.S. in Chemical Engineering from the Institue of Chemical Technology, Mumbai, India.
'We are delighted to welcome Shishir to our senior leadership team,' said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea Therapeutics. 'Shishir brings a remarkable track record of technical leadership across biologics, vaccines, and cell therapies, and his deep expertise in CMC and manufacturing operations will be instrumental as we advance our pipeline toward late-stage development. His proven ability to scale innovative therapies and build world-class technical capabilities will be invaluable as we prepare for Phase 3 readiness and continue to grow Marea into a leading cardioendocrine company.'
'I'm thrilled to join Marea at such an exciting moment in its growth,' said Dr. Gadam. 'The company's commitment to advancing first-in-class therapies for cardioendocrine diseases is both scientifically compelling and deeply meaningful. I look forward to working alongside this exceptional team to build and scale robust technical operations that will accelerate development and ultimately deliver transformative medicines to patients.'
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
Everest Group to Hold Second Quarter 2025 Earnings Conference Call on Thursday, July 31, 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. ('Everest') (NYSE: EG) will hold its second quarter 2025 earnings conference call on Thursday, July 31, 2025, beginning at 8:00 am Eastern Time. Dial in details can be obtained by completing the registration form available at: The call can be accessed via a live, listen only webcast at where a replay of the call will also be available. Everest will release financial results on July 30, 2025 after the NYSE market close. At that time, Everest's earnings release and financial supplement will be made available at About Everest Everest is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers' most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide. Everest common stock (NYSE: EG) is a component of the S&P 500 index. Additional information about Everest, our people, and our products can be found on our website at
Business Wire
13 minutes ago
- Business Wire
BIG 5 SPORTING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Big 5 Sporting Goods Corp.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Big 5 Sporting Goods Corp. (NasdaqGS: BGFV) to a partnership comprised of Worldwide Golf and Capitol Hill Group. Under the terms of the proposed transaction, shareholders of Big 5 will receive $1.45 in cash for each share of Big 5 that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
18 minutes ago
- Business Wire
BP Prudhoe Bay Royalty Trust Announces No Unit Payment for the Second Quarter of 2025 and Update on NYSE Delisting
HOUSTON--(BUSINESS WIRE)--BP Prudhoe Bay Royalty Trust (NYSE: BPT) announced that Unit holders of record on July 15, 2025 will not receive a dividend payment for the quarter ended June 30, 2025. As provided in the Trust Agreement, a quarterly royalty payment by Hilcorp North Slope, LLC to the Trust is the sum of the individual revenues attributed to the Trust as calculated each day during the quarter. The amount of revenue is determined by multiplying Royalty Production for each day in the calendar quarter by the Per Barrel Royalty for that day. Pursuant to the Trust Agreement, the Per Barrel Royalty for any day is the WTI Price for the day less the sum of (i) Chargeable Costs multiplied by the Cost Adjustment Factor and (ii) Production Taxes. For the three months ended June 30, 2025, the Per Barrel Royalty was calculated based on the following information: The average daily closing WTI price was below the 'break-even' price for the quarter, resulting in a negative value for the payment calculation for the quarter. However, as provided in the Trust Agreement, the payment with respect to the Royalty Interest for any calendar quarter may not be less than zero. As previously disclosed, the Trust terminated at 11:59 PM on December 31, 2024, and The Bank of New York Mellon Trust Company, N.A., as trustee (the 'Trustee'), has commenced the process of winding up the affairs of the Trust. The Trustee cannot predict when the wind-up of the Trust will be completed. Delisting from NYSE The Trust also announced that on June 30, 2025, it had received notification from the New York Stock Exchange ('NYSE') of its determination to suspend trading of the Trust's units of beneficial interest (the 'Units'), effective as of the close of trading on June 30, 2025, and to initiate proceedings to delist the Units. The determination to commence the delisting proceeding results from the Trust's inability to satisfy the continued listing compliance standards set forth under Rule 802.01C of the NYSE Listed Company Manual because the average closing price of the Units fell below $1.00 over a 30 consecutive trading-day period that ended on December 30, 2024, and the Trust was unable to regain compliance with the applicable standards within a cure period that concluded on June 30, 2025. As a result of the suspension, the Units began trading on July 1, 2025, under the symbol 'BPPTU' on the Pink Limited Market ('OTC Pink'), which is operated by OTC Markets Group, Inc. To be quoted on OTC Pink, a market maker must sponsor the security and comply with SEC Rule 15c2-11 before it can initiate a quote in a specific security. OTC Pink is a significantly more limited market than the NYSE, and the quotation of the Units on OTC Pink may result in a less liquid market available for existing and potential unitholders and could further depress the trading price of the Units. There is no assurance that an active market in the Units will develop on OTC Pink. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release are subject to a number of risks and uncertainties beyond the control of the Trust. These forward-looking statements include the Trust's expectations regarding the timing of the transition of the quotation of the Units to OTC Pink, expectations regarding the trading of the Units on OTC Pink and the Trust asset sale process. Descriptions of some of the risks that could affect the future performance of the Trust appear in the Trust's Annual Report on Form 10-K for the year ended December 31, 2024, the Trust's subsequent Quarterly Reports on Form 10-Q, and the Trust's other filings with the Securities and Exchange Commission (the 'SEC'). The Trust's annual, quarterly and other filed reports are or will be available over the Internet at the SEC's website at The Trustee undertakes no obligation to update forward-looking statements after the date of this report, except as required by law, and all such forward-looking statements in this report are qualified in their entirety by the preceding cautionary statements.
